How can homozygous familial hypercholesterolemia be distinguished from heterozygous familial hypercholesterolemia using clinical findings and genetic testing?

How to Distinguish Homozygous from Heterozygous Familial Hypercholesterolemia

The distinction between homozygous (HoFH) and heterozygous (HeFH) familial hypercholesterolemia is best made through genetic testing demonstrating biallelic pathogenic variants (two mutations) versus monoallelic variants (one mutation) in FH-related genes, combined with clinical phenotype assessment including LDL-C levels, age of presentation, and physical stigmata. 1

Genetic Testing: The Definitive Approach

Genetic testing should be the primary method to definitively distinguish HoFH from HeFH 1. The key genetic distinction is:

• HoFH: Two pathogenic variants (either true homozygote with identical mutations or compound heterozygote with two different mutations) in LDLR, APOB, PCSK9, or LDLRAP1 genes
• HeFH: Single pathogenic variant in one of these genes

The 2023 International Atherosclerosis Society guidelines provide Class 1A recommendation that genetic testing identifying pathogenic variants should be used whenever possible to make the diagnosis 1. This is particularly critical because:

• Clinical phenotypes can overlap
• Genetic confirmation enables accurate cascade screening of family members
• Treatment planning differs substantially between HoFH and HeFH
• Prognosis and cardiovascular risk stratification depend on accurate diagnosis

Important caveat: Recent evidence shows that approximately 0.9% of patients clinically diagnosed with HeFH actually have HoFH when comprehensive genetic testing including long-read sequencing is performed 2. This highlights the importance of thorough genetic evaluation, particularly in patients with more severe phenotypes than expected for HeFH.

Clinical Phenotype Differentiation

When genetic testing is unavailable or pending, clinical criteria can suggest HoFH versus HeFH 1:

LDL-Cholesterol Levels

HoFH diagnostic threshold:

• Untreated LDL-C >10 mmol/L (>400 mg/dl) measured on two occasions 1
• Note: Some genetically confirmed HoFH patients have LDL-C <13 mmol/L (<500 mg/dl), hence the lower threshold of 10 mmol/L is clinically appropriate 1
• Traditional threshold of >13 mmol/L (>500 mg/dl) is too restrictive 3

HeFH typical range:

• Adults: LDL-C >5 mmol/L (>190 mg/dl) 3
• Children: LDL-C >4.9 mmol/L (>190 mg/dl) 1

Age of Presentation and Physical Stigmata

HoFH presents earlier with more pronounced features 1:

• Cutaneous and tendon xanthomas appearing before age 10 years
• Arcus cornealis before age 10 years
• Cardiovascular disease manifestations in first or second decade of life
• Fatal coronary occlusions can occur before age 2 years 3

HeFH typically presents:

• Tendon xanthomas in adulthood (if present)
• Cardiovascular disease in 4th-6th decade without treatment
• Physical stigmata may be absent, especially if treated early 1

Family History Pattern

HoFH pattern 1, 3:

• Both parents have untreated LDL-C levels consistent with HeFH
• This is a critical diagnostic clue when genetic testing is unavailable

HeFH pattern:

• One parent typically affected
• Autosomal dominant inheritance pattern

Algorithmic Approach to Diagnosis

Step 1: Measure Untreated LDL-C

• Obtain fasting lipid profile on two occasions, 2 weeks to 3 months apart 1
• If patient is on statins/ezetimibe, calculate baseline LDL-C using validated imputation methods 3
• Exclude secondary causes (hypothyroidism, nephrotic syndrome, hepatic disease, medications) 1, 3

Step 2: Apply Clinical Criteria

Suspect HoFH if:

• Untreated LDL-C >10 mmol/L (>400 mg/dl) AND
• Physical stigmata (xanthomas, arcus) before age 10 years OR
• Both parents have elevated LDL-C consistent with HeFH 1

Suspect HeFH if:

• LDL-C >5 mmol/L in adults or >4.9 mmol/L in children AND
• One first-degree relative with elevated LDL-C or premature ASCVD OR
• Presence of tendon xanthomas in patient or family member 1, 3

Step 3: Obtain Genetic Testing

• Test LDLR, APOB, PCSK9, and LDLRAP1 genes 1, 3
• If single LDLR variant found, consider long-read sequencing to detect second variant that may have been missed 2
• Two pathogenic variants = HoFH
• One pathogenic variant = HeFH
• No variant found: Does not exclude FH; may be polygenic, variant of uncertain significance, or undetected mutation 3

Step 4: Assess Genotype-Phenotype Correlation

In genetically confirmed cases, determine mutation type 4, 5:

• Receptor-negative variants: Complete absence of LDL receptor function, higher LDL-C, worse prognosis
• Receptor-defective variants: Reduced but present LDL receptor activity, lower LDL-C, better response to statins/PCSK9 inhibitors

This distinction is critical for treatment planning, as receptor-negative HoFH patients respond poorly to LDLR-dependent therapies and require LDLR-independent approaches (lomitapide, evinacumab, apheresis) 5, 6.

Critical Pitfalls to Avoid

1. Don't rely solely on LDL-C cutoffs: Genetic HoFH can present with LDL-C <13 mmol/L, and some severe HeFH or polygenic hypercholesterolemia can have very high LDL-C 1

2. Don't miss HoFH in treated patients: Early statin treatment can mask the phenotype, making physical stigmata less apparent 1

3. Don't use adult HeFH criteria in children: Pediatric diagnostic criteria differ and adult scoring systems (Dutch Lipid Clinic Network, Simon Broome) should not be applied to children 1

4. Don't stop at finding one mutation: If clinical phenotype suggests HoFH but only one variant is found, pursue long-read sequencing or additional genetic testing 2

5. Don't forget to correct for Lp(a): Very high Lp(a) levels can elevate calculated LDL-C and mimic FH phenotype; consider Lp(a)-cholesterol correction in patients with markedly elevated Lp(a) 1

Immediate Management Implications

Once HoFH is diagnosed or strongly suspected 1, 3:

• Urgent referral to specialized lipid center (Class 1 recommendation)
• Complete cardiovascular evaluation including echocardiography
• Initiate maximal lipid-lowering therapy immediately (high-potency statin + ezetimibe)
• Plan for LDL apheresis if LDL-C remains >5 mmol/L on treatment, ideally started before age 5-8 years
• Consider LDLR-independent therapies (lomitapide, evinacumab) based on residual receptor function
• Annual cardiovascular surveillance with imaging

The distinction between HoFH and HeFH is not merely academic—it fundamentally changes prognosis, treatment intensity, and urgency of intervention, making accurate diagnosis through genetic testing a clinical imperative 1, 7.